Residual Tumor and Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France.
Department of Medical Oncology, Institut Curie, Paris, France.
Clin Cancer Res. 2019 Nov 15;25(22):6731-6741. doi: 10.1158/1078-0432.CCR-18-3017. Epub 2019 Sep 12.
High levels of tumor-infiltrating lymphocytes (TIL) before neoadjuvant chemotherapy (NAC) are associated with higher pathologic complete response (pCR) rates and better survival in triple-negative breast cancer (TNBC) and -positive breast cancer. We investigated the value of TIL levels by evaluating lymphocyte infiltration before and after NAC.
We assessed stromal TIL levels in 716 pre- and posttreatment matched paired specimens, according to the guidelines of the International TIL Working Group.
Pre-NAC TIL levels were higher in tumors for which pCR was achieved than in cases with residual disease (33.9% vs. 20.3%, = 0.001). This was observed in luminal tumors and TNBCs, but not in -positive breast cancers ( = 0.001). The association between pre-NAC TIL levels and pCR was nonlinear in TNBCs ( = 0.005). Mean TIL levels decreased after chemotherapy completion (pre-NAC TILs: 24.1% vs. post-NAC TILs: 13.0%, < 0.001). This decrease was strongly associated with high pCR rates, and the variation of TIL levels was strongly inversely correlated with pre-NAC TIL levels ( = -0.80, < 0.001). Pre-NAC TILs and disease-free survival (DFS) were associated in a nonlinear manner ( < 0.001). High post-NAC TIL levels were associated with aggressive tumor characteristics and with impaired DFS in -positive breast cancers (HR, 1.04; confidence interval, 1.02-1.06; = 0.001), but not in luminal tumors or TNBCs ( = 0.04).
The associations of pre- and post-NAC TIL levels with response to treatment and DFS differ between breast cancer subtypes. The characterization of immune subpopulations may improve our understanding of the complex interactions between pre- or post-NAC setting, breast cancer subtype, response to treatment, and prognosis.
新辅助化疗(NAC)前肿瘤浸润淋巴细胞(TIL)水平较高与三阴性乳腺癌(TNBC)和乳腺癌患者的更高病理完全缓解(pCR)率和更好的生存相关。我们通过评估 NAC 前后的淋巴细胞浸润来研究 TIL 水平的价值。
我们根据国际 TIL 工作组的指南,评估了 716 对预处理和治疗后配对标本中的基质 TIL 水平。
与残留疾病相比,达到 pCR 的肿瘤中 TIL 水平更高(33.9%比 20.3%,= 0.001)。这种情况在 luminal 肿瘤和 TNBC 中观察到,但在乳腺癌中未观察到(= 0.001)。在 TNBC 中,NAC 前 TIL 水平与 pCR 之间的关系是非线性的(= 0.005)。化疗完成后 TIL 水平下降(NAC 前 TILs:24.1%比 post-NAC TILs:13.0%,< 0.001)。这种下降与高 pCR 率密切相关,TIL 水平的变化与 NAC 前 TIL 水平呈强烈的负相关(= -0.80,< 0.001)。NAC 前 TIL 与无病生存期(DFS)呈非线性相关(< 0.001)。高 post-NAC TIL 水平与侵袭性肿瘤特征和乳腺癌的 DFS 受损相关(HR,1.04;置信区间,1.02-1.06;= 0.001),但在 luminal 肿瘤或 TNBC 中则不然(= 0.04)。
NAC 前和 post-NAC TIL 水平与治疗反应和 DFS 的关联在乳腺癌亚型之间存在差异。免疫亚群的特征可能会提高我们对 NAC 前或 post-NAC 环境、乳腺癌亚型、治疗反应和预后之间复杂相互作用的理解。